吡格列酮减少冷诱导的棕色脂肪葡萄糖摄取,尽管在培养的人脂肪细胞中诱导了棕色化:一项人体随机对照试验
该研究先在体外观察吡格列酮对人原代脂肪细胞棕色化的影响,随后在14名无心血管代谢疾病的瘦男性中开展盲法、安慰剂对照平行试验,随机接受安慰剂(乳糖,n=7,年龄22±1岁)或吡格列酮(45 mg/天,n=7,年龄21±1岁)28天。主要结局为冷刺激后棕色脂肪组织(BAT)活性的变化,结果显示吡格列酮组冷诱导的BAT最大标准化摄取值较安慰剂组显著降低(-57±6% vs -12±18%,p<0.05),BAT总葡萄糖摄取呈相似但非显著趋势(-50±10% vs -6±24%,p=0.097)。作者认为临床发现提示BAT活性降低可能促进吡格列酮等噻唑烷二酮类相关体重增加。
要点
- 吡格列酮在体外增加人脂肪细胞棕色化与脂肪生成。
- 临床试验中吡格列酮组冷诱导BAT最大标准化摄取值较安慰剂组显著降低(-57±6% vs -12±18%,p<0.05)。
- 吡格列酮组较安慰剂组增加总体重和去脂体重(p<0.05)。
核心结论
- 吡格列酮对BAT的作用在临床前模型与人体试验间存在差异,凸显在BAT治疗开发研究中尽早开展人体概念验证研究的必要性。
- 临床试验结果提示BAT活性降低可能促进吡格列酮及其他噻唑烷二酮类相关体重增加。
研究设计与样本
- 先体外观察吡格列酮处理培养的人原代肩峰锁骨下来源脂肪细胞是否诱导棕色化。
- 在Baker研究所临床研究实验室开展盲法、安慰剂对照平行试验,14名无心血管代谢疾病的瘦男性随机接受安慰剂(乳糖;n=7,年龄22±1岁)或吡格列酮(45 mg/天,n=7,年龄21±1岁)28天。
- 由Alfred医院工作人员通过电子随机数序列独立于研究进行分配,试验实施与数据分析人员对分组盲。
- 主要结局为干预前后经[18F]氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描评估的上胸部和颈部脂肪组织冷刺激BAT活性的变化。
主要发现
- 吡格列酮显著增加体外脂肪细胞棕色化和脂肪生成。
- 临床试验中,吡格列酮组冷诱导BAT最大标准化摄取值较安慰剂组显著降低(-57±6% vs -12±18%,p<0.05)。
- BAT总葡萄糖摄取呈相似但非显著趋势(吡格列酮组-50±10% vs 安慰剂组-6±24%,p=0.097)。
- 吡格列酮组较安慰剂组增加总体重和去脂体重(p<0.05)。
- 组间未检测到其他变化。
临床怎么用
- 作者认为,BAT活性降低可能促进吡格列酮及其他噻唑烷二酮类相关体重增加。
- 作者认为,在BAT治疗开发研究中应尽早开展人体概念验证研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Increasing brown adipose tissue (BAT) activity is a possible therapeutic strategy to increase energy expenditure and glucose and lipid clearance to ameliorate obesity and associated comorbidities. The thiazolidinedione (TZD) class of glucose-lowering drugs increase BAT browning in preclinical experimental models but whether these actions extend to humans in vivo is unknown. The aim of this study was to determine the effect of pioglitazone treatment on adipocyte browning and adaptive thermogenesis in humans. METHODS: We first examined whether pioglitazone treatment of cultured human primary subacromioclavicular-derived adipocytes induced browning. Then, in a blinded, placebo-controlled, parallel trial, conducted within the Baker Institute clinical research laboratories, 14 lean male participants who were free of cardiometabolic disease were randomised to receive either placebo (lactose; n = 7, age 22 ± 1 years) or pioglitazone (45 mg/day, n = 7, age 21 ± 1 years) for 28 days. Participants were allocated to treatments by Alfred Hospital staff independent from the study via electronic generation of a random number sequence. Researchers conducting trials and analysing data were blind to treatment allocation. The change in cold-stimulated BAT activity, assessed before and after the intervention by [18F]fluorodeoxyglucose uptake via positron emission tomography/computed tomography in upper thoracic and cervical adipose tissue, was the primary outcome measure. Energy expenditure, cardiovascular responses, core temperature, blood metabolites and hormones were measured in response to acute cold exposure along with body composition before and after the intervention. RESULTS: Pioglitazone significantly increased in vitro browning and adipogenesis of adipocytes. In the clinical trial, cold-induced BAT maximum standardised uptake value was significantly reduced after pioglitazone compared with placebo (-57 ± 6% vs -12 ± 18%, respectively; p < 0.05). BAT total glucose uptake followed a similar but non-significant trend (-50 ± 10% vs -6 ± 24%, respectively; p = 0.097). Pioglitazone increased total and lean body mass compared with placebo (p < 0.05). No other changes between groups were detected. CONCLUSIONS/INTERPRETATION: The disparity in the actions of pioglitazone on BAT between preclinical experimental models and our in vivo human trial highlight the imperative to conduct human proof-of-concept studies as early as possible in BAT research programmes aimed at therapeutic development. Our clinical trial findings suggest that reduced BAT activity may contribute to weight gain associated with pioglitazone and other TZDs. TRIAL REGISTRATION: ClinicalTrials.gov NCT02236962 FUNDING: This work was supported by the Diabetes Australia Research Program and OIS scheme from the Victorian State Government.
引用
- Loh RKC, Formosa MF, Eikelis N, et al. Pioglitazone reduces cold-induced brown fat glucose uptake despite induction of browning in cultured human adipocytes: a randomised, controlled trial in humans. Diabetologia. 2017. PMID: 29046921. doi:10.1007/s00125-017-4479-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。